Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Mitsubishi Estate Logistics REIT Investment Corp
TSE:3481
|
JP |
|
C
|
CaoCao Inc
HKEX:2643
|
CN |
|
Haitong Securities Co Ltd
SSE:600837
|
CN |
Cumberland Pharmaceuticals Inc
Total Liabilities & Equity
Cumberland Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
Total Liabilities & Equity
$76.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities & Equity
$199.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities & Equity
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities & Equity
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities & Equity
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities & Equity
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Cumberland Pharmaceuticals Inc
Glance View
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. The company is headquartered in Nashville, Tennessee and currently employs 83 full-time employees. The company went IPO on 2009-08-11. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.
See Also
What is Cumberland Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
76.8m
USD
Based on the financial report for Dec 31, 2025, Cumberland Pharmaceuticals Inc's Total Liabilities & Equity amounts to 76.8m USD.
What is Cumberland Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-2%
Over the last year, the Total Liabilities & Equity growth was 2%. The average annual Total Liabilities & Equity growth rates for Cumberland Pharmaceuticals Inc have been -6% over the past three years , -4% over the past five years , and -2% over the past ten years .
